ecrin-mdr-crcClinical1999Cancer-Bowel-Back passage (rectum) or large bowel (colon)Metastatic colorectal cancer treated with FOLFOXIRICancer-bowel-back Passage (rectum) Or Large Bowel (colon)Metastatic Colorectal Cancer Treated With FolfoxiriObservationalhttps://newmdr.ecrin.org/Study/2454318Italy5ECRIN MDRCompletedfalseEvaluation of initially unresectable metastatic colorectal cancer patients treated with 5-fluorouracil/leucovorin, oxaliplatin and irinotecan (FOLFOXIRI) followed by radical surgery of metastases.Interventions: Observation: metastatic colorectal cancer patients who have been treated in first-line with FOLFOXIRI (a triple drug combination of irinotecan 165 mg/square meter (sqm) endovenous (ev) in 1 hour, oxaliplatin 85 mg/sqm ev in 2 hours and 5-fluorouracil 3200 mg/sqm as a 48-hour continous infusion ev plus leucovorin 200 mg/sqm ev in 2 hours, every 14 days for 12 cycles) and who underwent radical surgical resection of metastases will be followed up yearly for 5 years after the diagnosis of disease to collect their survival status. Primary outcome(s): Overall survival[Anually for 5 years after diagnosis] Study Design: Purpose: Natural history;Duration: Longitudinal;Selection: Defined population;Timing: Prospective1999-05-152454318ACTRN12608000615381